Our second treatment strategy, however, was much more effective and the combination of plerixafor and cytarabine demonstrated a significant improvement in leukemic control compared to cytarabine alone, suggesting that inhibition of the bone marrow microenvironment may be a means to improve upon the poor overall and disease-free survival in infant MLL-R ALL. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.